This appears to be another very expensive drug with possibly scant potential to really help patients, and it comes with a very high price tag.  It may represent a baby step toward better treatment, but until such time as a drug has real potential in slowing the progression of Alzheimer's, it's not worth tens of thousands of dollars per patient each year. We need real progress for these patients, not expensive and risky treatments with a low cost/reward profile.

This appears to be another very expensive drug with possibly scant potential to really help patients, and it comes with a very high price tag.  It may represent a baby step toward better treatment, but until such time as a drug has real potential in slowing the progression of Alzheimer's, it's not worth tens of thousands of dollars per patient each year. We need real progress for these patients, not expensive and risky treatments with a low cost/reward profile.

user
no
assistant